The Food and Drug Administration (FDA) granted accelerated approval to tafasitamab-cxix, a CD19-directed cytolytic antibody, indicated in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

The efficacy of tafasitamab-cxix with lenalidomide was evaluated in L-MIND (NCT02399085), an open label, multi-centre single-arm trial in 81 patients.

Patients received tafasitamab-cxix 12 mg/kg intravenously with lenalidomide (25 mg orally on days 1 to 21 of each 28-day cycle) for maximum of 12 cycles, followed by tafasitamab-cxix as monotherapy.

Efficacy was based on best overall response rate (ORR), defined as complete and partial responders and response duration, as assessed by an independent review committee.

The best ORR in 71 patients with a diagnosis of DLBCL confirmed by central pathology was 55% (95% CI: 43%, 67%), with complete responses in 37% and partial responses in 18% of patients.

Median response duration was 21.7 months (range: 0, 24).

The most common adverse reactions (≥20%) were neutropenia, fatigue, anaemia, diarrhoea, thrombocytopenia, cough, pyrexia, peripheral oedema, respiratory tract infection, and decreased appetite.

The recommended tafasitamab-cxix dose is 12 mg/kg as an intravenous infusion.

View full prescribing information for tafasitamab-cxix here. 

Source: The Food and Drug Administration (FDA)